Clinical Trial NCT04965597
Trial
Fred Hutchinson Cancer Center – BMTCTN1904
Clinical trial ID
NCT04965597
Drug name
Treosulfan, Fludarabine and rATG
Company:
Fred Hutchinson Cancer Center
Drug trade name
---
Phase of study
2
Current status
Recruiting
Start
04/2022
Substance
cytostatics, cytotoxines and antibodies
Research question
---
Delivery method of drug
i.v.
Frequency
6 days daily until transplantation, following 180 days of prophylaxis
Clinical trial locations
USA